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Efficient lymphoreticular prion propagation requires PrP(c) in
stromal and hematopoietic cells
Abstract
In most prion diseases, infectivity accumulates in lymphoreticular organs early after infection. Defects
in hematopoietic compartments, such as impaired B-cell maturation, or in stromal compartments, such
as abrogation of follicular dendritic cells, can delay or prevent lymphoreticular prion colonization.
However, the nature of the compartment in which prion replication takes place is controversial, and it is
unclear whether this compartment coincides with that expressing the normal prion protein (PrP(c)). Here
we studied the distribution of infectivity in splenic fractions of wild-type and fetal liver chimeric mice
carrying the gene that encodes PrP(c) (Prnp) solely on hematopoietic or on stromal cells. We
fractionated spleens at various times after intraperitoneal challenge with prions and assayed infectivity
by bioassay. Upon high-dose challenge, chimeras carrying PrP(c) on hematopoietic cells accumulated
prions in stroma and in purified splenocytes. In contrast, after low-dose challenge ablation of Prnp in
either compartment prevented splenic accumulation of infectivity, indicating that optimal prion
replication requires PrP(c) expression by both stromal and hematopoietic compartments.
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In most prion diseases, infectivity accumulates in lymphoreticular organs early after infection. Defects in
hematopoietic compartments, such as impaired B-cell maturation, or in stromal compartments, such as abro-
gation of follicular dendritic cells, can delay or prevent lymphoreticular prion colonization. However, the na-
ture of the compartment in which prion replication takes place is controversial, and it is unclear whether this
compartment coincides with that expressing the normal prion protein (PrPc). Here we studied the distribution
of infectivity in splenic fractions of wild-type and fetal liver chimeric mice carrying the gene that encodes PrPc
(Prnp) solely on hematopoietic or on stromal cells. We fractionated spleens at various times after intraperi-
toneal challenge with prions and assayed infectivity by bioassay. Upon high-dose challenge, chimeras carrying
PrPc on hematopoietic cells accumulated prions in stroma and in purified splenocytes. In contrast, after low-
dose challenge ablation of Prnp in either compartment prevented splenic accumulation of infectivity, indicating
that optimal prion replication requires PrPc expression by both stromal and hematopoietic compartments.
Prion diseases are invariably lethal, transmissible neurode-
generative conditions that affect humans and many animal
species. The causative infectious agent, termed prion (37), was
proposed to be identical with PrPSc, a pathological conformer
of the cellular protein PrPc encoded by the cellular gene Prnp.
While the central nervous system is the only site of histo-
logically discernible damage, PrPc is expressed in many other
sites, notably including lymphocytes. Intracerebral (i.c.) or pe-
ripheral administration of prions to mice causes a rise of in-
fectivity in spleen and in other lymphatic organs long before
the development of neurological symptoms and neuropatho-
logical changes (21). Moreover, peripheral inoculation routes
are likely to initiate most forms of spongiform encephalopa-
thies such as sheep scrapie, bovine spongiform encephalopa-
thy, iatrogenic Creutzfeldt-Jakob disease (CJD) and new-vari-
ant CJD. Intraperitoneal (i.p.) inoculation has been extensively
used to study the pathogenesis of transmissible spongiform
encephalopathies because it causes rapid accumulation of in-
fectivity in secondary lymphatic organs (12, 16, 17). The im-
mune system is important for pathogenesis: development of
scrapie disease after i.p. inoculation, in contrast to i.c. chal-
lenge, is impaired in SCID mice (30) and B-cell-deficient mice
(24) and, to a lesser extent, after splenectomy (21). These and
many other studies argue for an active role of the lymphore-
ticular system in the transport of scrapie infectivity from the
periphery to the central nervous system.
The question of which compartments within lymphoreticular
tissues support prion replication is of immediate relevance to
public health: contamination with new-variant CJD prions of
germinal centers in lymph node and tonsillar follicles, for ex-
ample, might call for precautionary measures in handling, re-
usage, and sterilization of surgical instruments. Conversely,
infection of germinal center lymphocytes with prions may raise
the question of whether these cells carry infectivity into the
bloodstream, a question of great importance to transfusion
medicine (1).
Here we have investigated the role of various spleen cell
subsets in the preclinical phase of mouse scrapie. We demon-
strate that—within the potential limitations of experiments
with fetal liver chimeras—prion infectivity can be associated
with splenic lymphocytes devoid of Prnp and that congruently
with previous results (5), chimeras of PrP-deficient hosts with
PrP-expressing hematopoetic cells are able to accumulate
chronically prions in the spleen for at least 200 days after
inoculation. Furthermore, we show that efficient lymphoreticu-
lar prion propagation requires PrPc in stromal and hematopoi-
etic cells.
MATERIALS AND METHODS
Preparation of the RML standard inoculum. Rocky Mountain Laboratory
(RML; passage 4.1) mouse-adapted scrapie prion inoculum was prepared from
brains of terminally sick CD-1 mice (incubation time, 154 6 12 days) as described
previously (10). Brains (11.5 g, total) of terminally sick mice were pooled and
homogenized with 1.2- and 0.7-mm syringes in 103.5 ml of sterile 0.32 M sucrose
(without heat inactivation or Sarkosyl treatment). This 10% homogenate was
defined as the standard RML inoculum. To determine the infectivity titer, serial
10-fold dilutions of our standard inoculum were prepared in sterile phosphate-
buffered saline (PBS) containing 5% bovine serum albumin (BSA) and injected
i.c. into 4 tga20 indicator mice (15) (30 ml per mouse). The titer of the standard
inoculum (7.9 log10 of 50% lethal dose [LD50]/ml, corresponding to 8.9 log
LD50/g of brain tissue) was determined by the 50% endpoint calculation method
(42). The relationship y 5 11.45 2 0.088x (y, log LD50 per milliliter of homog-
enate; x, incubation time in days to terminal disease) was calculated by linear
regression (38). All animal experiments were performed according to the law of
the Kanton of Zu¨rich and were approved by the Committee on Animal Exper-
imentation.
Construction of fetal liver chimeric mice. Eight-week-old mice were reconsti-
tuted with lymphohemopoietic stem cells (LSCs) derived from fetal livers. Timed
pregnancies of wild-type and Prnpo/o mice served to produce mouse embryos.
Fetal livers were collected at embryonic day 14.5 to 15.5 in Dulbecco’s modified
Eagle’s medium (DME) and dissociated using 1.2- and 0.7-mm syringes. After a
short spin (10 s, 170 3 g), the supernatant containing fetal liver cells (FLCs) was
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collected and diluted in DME. FLCs (2 3 107 to 3 3 107 cells) were injected into
the recipient’s tail vein (injection volume, 100 ml). Recipients had been lethally
irradiated with 900 rad 24 h earlier. Prnp1/1 ([129/Sv 3 C57BL/6]F1) and Prnpo/o
(10) ([129/Sv 3 C57BL/6]Fn) mice served as recipients and as donors.
Flow cytometric analysis of PBLs of fetal liver cell-reconstituted mice. Six to
eight weeks after grafting, successful reconstitution was assessed by the PrP
status of B and T cells (Fig. 2). Peripheral blood lymphocytes (PBLs) were
incubated with monoclonal 6H4 mouse anti-PrP antibody (28) (Prionics) diluted
1:200 in fluorescence activated cell sorter (FACS) buffer (PBS, 2% fetal calf
serum, 10 mM EDTA [pH 8], 15.3 mM NaN3) and detected with fluorescein
isothiocyanate (FITC)-goat anti-mouse immunoglobulin G1 (IgG1). Cells were
separated in two fractions and additionally stained for B or T cells. We used
phycoerythrin (PE)-anti-mouse CD19 (clone 1D3) for B cells and PE-anti-mouse
CD3e (clone 500A2) antibodies for T cells. Lysis of the red blood cells was
performed with FACS lysing solution (Becton Dickinson) according to the man-
ufacturer’s protocol. All data were acquired on a FACSCalibur (Becton Dick-
inson). Analyses were done with CELLQuest (Becton Dickinson), WinList (Ver-
ity Software House, Inc.), and WinMDI 2.8 (Scripps Research Institute; http://
facs.scripps.edu) analysis software. PBLs of Prnpo/o and of wild-type mice as well
as omission of primary antibody and unstained cells served as controls. A total of
66 successfully reconstituted and control mice (Table 1) were inoculated i.p. with
100 ml of RML inoculum containing either 6 or 3 log LD50 of prions.
Immunofluorescence analyses of spleen sections. At various time points (34,
60, 90, 200, and 360 days), groups of two to three animals per experimental setup
were analyzed. Spleens were sampled, and tissue for preparation of whole spleen
homogenates, immunofluorescence analyses, and cellular fractions was collected.
Two-color immunofluorescence of frozen sections was performed by using rat
anti-mouse FDC-M1 antibody (29) (clone 4C11; 1:300 in PBS–0.15% BSA; a gift
from M. Kosco-Vilbois, Glaxo-Wellcome Research and Development S.A., Plan-
les-Ouates, Switzerland) for follicular dendritic cells (FDCs) and a polyclonal
rabbit anti-mouse PrP serum (XN; 1:1,000 in PBS–0.15% BSA). Primary anti-
bodies were detect with FITC-F(ab9)2 fragments of goat anti-rat IgG (heavy plus
light chain [H1L]) (1:100 in PBS) or Alexa 546-goat anti rabbit IgG (H1L)
(1:500 in PBS). Omission of primary antibodies or rabbit preimmune serum
served as a control. Sections were then analyzed on an immunofluorescence
microscope, and representative samples were selected for confocal laser scanning
microscopy (Fig. 3) with Leica model DM IRB E inverted microscope and
confocal laser scanning system TCS4D.
Preparation of total spleen homogenates and splenic cellular and stromal
fractions. To prepare total spleen homogenates, spleen tissue was hand-homog-
enized as a 10% (wt/vol) suspension in 0.32 M sucrose with a microhomogenizer
(Pellet Mixer 1.5 ML; Treff AG) for 10 to 15 min, then passed several times
through 0.7-mm needles, and spun for 1 min at 230 3 g in 1.5-ml Eppendorf
tubes. The supernatant was diluted 10 times with PBS–5% BSA to produce a 1%
homogenate.
Spleen samples of mice belonging to the same reconstitution group and killed
after the same incubation time were pooled to produce cellular fractions. Spleen
cells were obtained by forcing spleens through a 40-mm-mesh nylon net into a
petri dish prefilled with DME. The stromal fraction was recovered from the net
by scraping, and a 10% (wt/vol) homogenate in PBS–5% BSA containing 0.1%
Sarkosyl was prepared by forcing the suspension through an 1.2-mm needle. The
homogenate was digested with collagenase D (1 mg/ml) for 30 min at 37°C,
sonicated (Branson Sonifier; maximal output) 7 to 14 times for 2 min in 1.5-ml
Micro Tubes, and then diluted 10 times with PBS–5% BSA to give a 1% (wt/vol)
homogenate. Spleen cells were centrifuged (300 3 g, 10 min, 4°C), counted, and
dissolved in magnetic cell sorting (MACS) buffer (PBS, 0.5% BSA, 2 mM
EDTA). To purify B cells, spleen cells were incubated with Mouse CD45R
(B220) MicroBeads (catalog no. 495-01; Miltenyi Biotec Inc.) according to the
manufacturer’s protocol. After washing, cells were resuspended in MACS buffer
and applied to a prefilled and washed MACS VS1 separation column (Miltenyi
Biotec) fixed onto a VarioMACS (Miltenyi Biotec). Unlabeled cells passed
through and were collected as the negative fraction. The column was removed
from the VarioMACS, and B cells were flushed out. For purification of T cells,
the negative fraction recovered from the B-cell sorting was incubated with mouse
CD90.2 (Thy-1.2) MicroBeads (catolog no. 491-01; Miltenyi Biotec), and T cells
were purified as described above. Unlabeled cells were again rinsed out with
MACS buffer and collected as non-B/T cells. All purified cells were counted and
diluted in the appropriate volume of PBS–5% BSA to adjust the concentration
to 2 3 105 or 106 cells per 30 ml, depending on the number of total cells. The
purity of the collected cell fractions was confirmed by FACS analysis (Fig. 4A).
Each splenic fraction was labeled for B cells (PE-anti-mouse CD45R) and for T
cells (PE-anti-mouse CD90.2); unstained samples served as controls. Data were
acquired with a MoFlo cell sorter (Cytomation). Analyses were done with Win-
List.
Isolation of WBCs from whole blood. White blood cells (WBCs) were isolated
from whole blood by density gradient centrifugation using Lympholyte-M me-
dium (Cedarlane Laboratories). At the time points indicated, blood was taken
and samples of the same experimental group were pooled. Cells were adjusted to
maximally 2 3 107 nucleated cells/ml in MACS buffer, and gradient centrifuga-
tion was performed as specified by the manufacturer (Cedarlane Laboratories).
TABLE 1. Prion load of spleens in individual FLC-reconstituted mice
Mice RML inoculum(log LD50)
Days after
inoculation
No. of animals
inoculated
Splenic infectivity
(log LD50)
No. of indicator animals succumbing to scrapie/no. inoculated
(mean incubation time 6 SD [days])
Prnp1/13Prnpo/o 6 34 2 5.5, ,1.5a 4/4 (80.8 6 9.0), 2/8 (133, 135)
60 3 5.6, 5.0, 4.3 4/4 (80.3 6 4.5), 4/4 (87.5 6 9.1), 3/3 (95.7 6 12.2)
90 3 NDb ND
200 4 5.0, 4.9, 4.0, ND 4/4 (88.8 6 8.1), 4/4 (89.3 6 5.9), 4/4 (101.5 6 9.0), ND
Prnp1/13Prnpo/o 3 34 3 ,1.5, ,1.5, ND 0/4, 0/3, ND
60 3 ,1.5, ,1.5, ,1.5 0/4, 0/3, 0/3
90 3 ND ND
360 5 ND ND
Prnpo/o3Prnp1/1 6 34 3 7.1, 6.1, ND 4/4 (65.8 6 3.5), 4/4 (77.0 6 3.8), ND
60 2 6.6, 6.5 3/3 (71.0 6 11.1), 4/4 (72.3 6 3.0)
90 2 6.6, 6.1 4/4 (69.5 6 7.9), 3/3 (75.3 6 5.5)
200 2 7.0, 7.2 4/4 (64.8 6 1.5), 4/4 (62.0 6 2.3)
Prnpo/o3Prnp1/1 3 34 3 ,1.5, ,1.5, ,1.5 0/4, 0/4, 0/4
60 2 ND ND
90 2 ND ND
360 2 ,1.5, ND 0/4, ND
Prnpo/o3Prnpo/o 6 34 3 ,1.5, ,1.5,a ND 0/4, 3/4 (155, 163, 178),c ND
60 2 ,1.5, ,1.5 0/4, 0/4
200 2 ND ND
Prnpo/o3Prnpo/o 3 360 5 ND ND
Prnp1/1 6 34 2 6.5, 5.3 4/4 (69.0 6 2.0), 3/3 (83.0 6 6.2)
200 3 ND ND
Prnp1/1 3 34 2 5.8, 5.8 3/3 (77.3 6 5.9), 4/4 (77.3 6 4.7)
230 3 ND ND
a If one or more animals survived .180 days, the titer was assumed to be close to the detection limit of the bioassay (,1.5).
b ND, not determined.
c The development of scrapie disease in these indicator animals is most likely due to residual inoculum of the primary inoculation.
7098 KAESER ET AL. J. VIROL.
The lymphocyte layer at the interface was recovered, counted, and diluted to the
appropriate concentration (2 3 105, 5 3 105, or 106 cells per 30 ml).
Infectivity bioassays with tga20 indicator animals. All assays were done with
1% spleen homogenates, spleen cell purifications, stromal homogenates, and
WBCs. Whole spleen homogenates (1%, wt/vol), spleen cells (106 cells), stromal
fractions (1%, wt/vol), spleen cell purifications (B cells, T cells, and non-B/T
cells; 2 3 105 or 106 cells per fraction), and WBCs (2 3 105 or 106 cells per
fraction) were inoculated i.c. (30 ml of each) into groups of three or four tga20
indicator mice (15). Animals were monitored for neurological symptoms and
killed after development of terminal scrapie. Scrapie disease in indicator mice
was confirmed by typical histopathology. The relationship y 5 11.45 2 0.088x (y,
log LD50 per milliliter of homogenate; x, incubation time in days to terminal
disease) was used to calculate the level of infectivity (15, 38) within these
homogenates. Prion contents are indicated per spleen; spleen weights were
calculated according to the determined weight of the stromal fraction, which was
considered to be 10% of the weight of a total spleen (13). Spleen cells consist
approximately of 80% lymphocytes (30% T cells and 70% B cells) and 20%
nonlymphocytic cells (4, 6).
ELISA for detection of anti-PrP antibodies. Sera were analyzed by indirect
enzyme-linked immunosorbent assay (ELISA). Wells of 384-well plates were
coated with 0.105 mg of recombinant PrP23–231 diluted in 50 ml of PBS overnight
at 4°C. After three washes with ELISA buffer (PBS containing 0.1% Tween), the
residual binding capacity of the plate was blocked with 100 ml of ELISA buffer
containing 5% milk powder for 2 h at room temperature (RT). Extensive wash-
ing with ELISA buffer removed the unbound protein. Then the plates were
incubated for 2 h at RT with three dilutions of each mouse serum (1:25, 1:75, and
1:225, in 50 ml of ELISA buffer containing 1% BSA), using three wells for every
dilution. Plates were washed four times with ELISA buffer before incubating
with the second antibody (horseradish peroxidase-conjugated rabbit anti-mouse
IgG-IgA-IgM [H1L]; 0.075 mg per well in 50 ml of ELISA buffer–1% BSA for 2 h
at RT). The plates were developed with 50 ml of 2,29-azino-bis(3-ethylbenzthia-
zoline-6-sulfonic acid) (ABTS; 5 mg of ABTS in 50 ml of 0.1 M NaH2PO4) [pH
4] containing 0.055% H2O2 for 50 min at RT, and optical density was then
measured with a LAMBDA E ELISA reader (MWG Biotech AG) at 405 nm.
The antibody titer in the serum of a terminally sick 129Sv 3 C57BL/6 mouse was
considered to be the background titer. Omission of the sera, omission of the
secondary antibody, uncoated wells, dilutions of 6H4 antibody (Prionics) (28),
and a serum of a Prnp-null mouse with a PrPc-expressing brain graft (8) known
to contain high levels of anti PrP antibodies served as controls.
PCR of splenic fractions. Analyses were performed postmortem on spleen
cells, B cells, T cells, and non-B/T cells. Cells (3 3 106) were digested with
proteinase K (18 mg/ml) overnight at 55°C in 100 ml of digestion buffer (50 mM
KCl, 10 mM Tris HCl [pH 9], 0.4% NP-40, 0.4% Tween 20). Proteinase K was
inactivated for 12 min at 75°C, and the samples were centrifuged at 5,000 3 g for
12 min. PCR was carried out with primers P3 (ATT CGC AGC GCA TCG CCT
TCT ATC GCC), complementary to the 39 end of the Neo cassette of the
knockout allele; P10 (GTA CCC ATA ATC AGT GGA ACA AGC CCA GC),
complementary to the 59 end of the Prnp reading frame; and 39nc (ATA ACC
CCC TCC CCC AGC CTA GAC CAC GAG), complementary to genomic
sequences adjacent to the 39 end of the Prnp reading frame (15). PCR conditions
were 94°C for 5 min 30 s, then 35 cycles of 94°C for 45 s, 55°C for 45 s, and 72°C
for 1 min, followed by extension at 72°C for 7 min. Amplification with primer pair
P10-39nc resulted in a 550-bp DNA fragment representing the Prnp1 allele;
amplification with primer pair P3-39nc resulted in a 350-bp DNA fragment
showing the presence of the Prnp0 allele.
RESULTS
Establishment of a standard prion inoculum. All inocula-
tion experiments described in this study were performed with
the RML 4.1 prion inoculum, which was derived by fourfold
serial passage in CD-1 mice of a brain homogenate originally
donated by S. Prusiner (San Francisco, Calif.). This homoge-
nate originates from the Chandler mouse-adapted scrapie
strain. The prion titer of the RML 4.1 inoculum was deter-
mined by the endpoint dilution assay. We transmitted serial
dilutions (1021 to 1028 in log10 steps) of the isolate into tga20
indicator mice (Fig. 1). We calculated the level of infectivity
according to the 50% endpoint (42) and found it to be 8.9 log
LD50/g of brain tissue. Because the standard inoculum was
derived by diluting brain homogenate 1:10 in 0.32 M sucrose,
the titer of the inoculum is 7.9 log LD50/ml. The transmission
results evidenced a linear relationship between the logarithmic
size of inoculum and incubation time over a dilution range of
1022 to 1026 (Fig. 1) according to the following empirically
derived formula: y 5 11.45 2 0.088x (y, log LD50 per milliliter
of homogenate; x incubation time in days to terminal disease)
(38). This relationship was then used to calculate the level of
prions in materials containing an unknown amount of infectiv-
ity.
Expression of PrPc in lymphocyte subsets of fetal liver chi-
meras. To produce chimeric mice expressing PrPc on lympho-
cytes but not on stromal cells such as FDCs, or vice versa, FLCs
of the Prnpo/o or Prnp1/1 genotype, were administered intra-
venously to Prnpo/o or Prnp1/1 mice that had been lethally
irradiated.
Radioresistant splenic cells, including FDCs, were expected
to display the PrP phenotype of the host (49), whereas cells
derived from the incoming LSCs showed the PrP phenotype of
the FLC donors. This was studied by flow cytometric analysis
of PBLs 6 to 8 weeks after grafting using monoclonal anti-PrP
antibody 6H4 (Fig. 2) (28). Reconstitution of Prnpo/o mice with
Prnp1/1 FLCs (creating Prnp1/13Prnpo/o mice) yielded 35.5%
6H4-positive B lymphocytes and 12.0% 6H4-positive T lym-
phocytes in peripheral blood, and 6H4 two-color FACS pro-
files were superimposable to those of wild-type mice. In con-
trast, wild-type mice reconstituted with PrP deficient FLCs
(Prnpo/o3Prnp1/1 mice) exhibited 2.9% 6H4-positive B cells
and 0.8% 6H4-positive T cells when the same instrument set-
tings and gates were used (Fig. 2). The latter findings were
identical to the staining pattern of Prnpo/o PBLs and were most
probably due to a small amount of nonspecific binding of the
6H4 antibody to lymphocytes.
FIG. 1. Endpoint titration of the standard inoculum used for this
study. Serially diluted brain homogenate of terminally sick CD-1 mice
(30 ml) was injected i.c. into tga20 mice. Each circle represents one
indicator mouse that succumbed to scrapie disease; each cross corre-
sponds to a healthy animal. The 50% endpoint served to ascertain the
titer of the 10% standard inoculum (42). The relationship y 5 11.45 2
0.088x (y, log LD50 per milliliter of homogenate; x, incubation time in
days to terminal disease) was determined by linear regression (38).
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PrP topography in spleens of scrapie-infected chimeras.
Groups of 10 to 15 chimeric mice and corresponding controls
(Table 1) were inoculated i.p. with either a saturating dose (1
mg of RML 4.1 brain homogenate diluted in 100 ml 0.32 M
sucrose, corresponding to 6 log LD50 as calculated using the
data shown in Fig. 1) or a limiting dose (3 log LD50) of RML
scrapie prions. At various time points after inoculation (34, 60,
90, 200, and 360 days), two to three mice per group were
analyzed. Cryoconserved spleen sections (10 mm in thickness)
were stained with antibody FDC-M1 to FDCs (29) and poly-
clonal serum against PrP and then analyzed by immunofluo-
rescence microscopy. Representative sections were selected
for confocal laser scanning microscopy (Fig. 3). In spleens of
noninoculated or scrapie-infected wild-type mice (naive or
grafted with Prnpo/o FLCs), signals for FDCs and PrP colocal-
ized precisely (Fig. 3, first and fourth rows) FDCs are situated
in germinal centers: accordingly, the staining for PrP was con-
fined to these structures. In contrast, Prnpo/o mice grafted with
Prnp1/1 FLCs (Prnp1/13Prnpo/o), which express PrPc on
LSCs but not on stromal cells, displayed PrP-positive cells both
in FDC-M1-positive areas and in FDC-M1-negative compart-
ments that surrounded the germinal centers (Fig. 3, third row).
Distribution of prions in spleens of fetal liver chimeric mice.
The findings described above indicate that 6H4 immunoreac-
tivity, at least in fetal liver chimeras, is not confined to germinal
centers. We therefore set out to determine the nature of 6H41
non-germinal-center cells and assess whether these cells are
associated with prion infectivity in addition to PrP immunore-
activity.
Spleens were fractionated into stroma and spleen cells (here
defined as cells that can be recovered as a suspension after
passing spleens through a mesh). Spleen cells were then sep-
arated into B cells, T cells, and a non-B/T-cell fraction. Each
fraction was tested for purity by FACS analysis with anti-
CD45R (B220) and anti-CD90.2 (Thy1.2) antibodies. In each
fraction, purity was .97% of the sorted cell type (Fig. 4A).
Cross-contamination of the purified cell fractions (e.g., T cells
contaminating the B-cell fraction, or vice versa) could be ex-
cluded to a large extent. Whole spleen homogenates and cell
subsets were then transmitted i.c. to groups of 3 to 4 tga20
indicator mice. The relationship y 5 11.45 2 0.088x (y, log
LD50/per milliliter of homogenate; x, incubation time in days to
terminal disease) was used to calculate the level of infectivity
FIG. 2. Flow cytometric analysis of PrPc expression on PBLs. Reconstitution resulted consistently in CD19-positive B and CD3e -positive T
lymphocytes of graft origin, as confirmed by the expression of PrPc and detected by 6H4 antibody staining. Numbers indicate the percentage of
cells in the quadrants. Analyses were done on WBCs 6 to 8 weeks after the grafting procedure described. Ordinate, logarithm of fluorescence
intensity for B cells (CD19) or T cells (CD3 e ); abscissa, logarithm of fluorescence intensity for PrP (6H4).
FIG. 3. Confocal double-color immunofluorescence analysis of splenic germinal centers of reconstituted and inoculated mice and noninocu-
lated controls. Thirty-four days after i.p. scrapie challenge, spleen sections of fetal liver chimeras were stained with FDC-M1 antibody to FDCs
(green color, left column) and XN polyclonal antiserum to PrP (red color, middle column). Noninoculated Prnp1/1 ([129Sv 3 C57BL/6]F1) and
Prnpo/o ([129Sv 3 C57BL/6]Fx) mice served as controls. In spleens of noninoculated wild-type mice or prion-infected wild-type mice grafted with
Prnpo/o FLCs (Prnpo/o3Prnp1/1), the signal for PrP is confined to FDC-M1-positive areas (yellow color, first and fourth rows). Instead, Prnpo/o
mice reconstituted with Prnp1/1 FLCs (Prnp1/13Prnpo/o) show PrP-positive cells both in FDC-M1-positive areas (yellow color, third row) and in
FDC-M1-negative compartments surrounding the follicular dendritic network (red color, third row).
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(8, 38) within these homogenates and, consequently, the dis-
tribution of prions within spleens.
In wild-type mice, prions replicate in secondary lymphatic
organs and a plateau level of splenic infectivity is reached early
after i.p. inoculation (20, 40). In this study, we recovered 5.3 to
6.5 log LD50 prions per spleen 34 days after inoculation with a
saturating (6 log LD50) and a limiting (3 log LD50) dose (Table
1), indicating that both inoculum sizes were sufficient to estab-
lish chronic spleen infection of wild-type mice. In agreement
with previous experiments (5) the infectious agent was cap-
tured and stored in spleens of Prnpo/o mice carrying LSCs from
Prnp1/1 mice (Prnp1/13Prnpo/o; Table 1). Prion amounts
ranging between 4 and 5.5 log LD50 per spleen could be mea-
sured throughout a time frame of 34 to 200 days after periph-
eral inoculation with 6 log LD50. We observed only one excep-
tion: one spleen of a Prnp1/13Prnpo/o chimera sacrificed 34
days after scrapie challenge contained very little prion infec-
tivity (Table 1). When prion loads were measured in individual
spleen cell fractions, the highest loads were detected in stromal
fractions, whereas Prnp1/1 spleen cells contained only low
amounts of prion infectivity (Fig. 4B). The prion load in
MACS-sorted splenic B and T cells amounted to only 10- to
100 infectious units and was therefore close to the detection
threshold of the assay. In the same experimental group
(Prnp1/13Prnpo/o), i.p. inoculation with 3 log LD50 of scrapie
prions resulted in noninfectious spleens (Table 1).
In wild-type mice grafted with FLCs derived from Prnp-null
(Prnpo/o3Prnp1/1) mice and inoculated with 6 log LD50 of
primary inoculum, higher splenic infectivity loads than in the
reciprocal (Prnp1/13Prnpo/o) chimeras were detected at all
time points. Infectivity rose to ca. 7 log LD50 per total spleen
34 days after i.p. challenge and stayed constant throughout
the experimental observation time (Table 1). As in Prnp1/13
Prnpo/o chimeras, in Prnpo/o3Prnp1/1 fetal liver chimeras 3 log
LD50 i.p. failed to produce disease in indicator animals (Table
1). In Prnpo/o3Prnp1/1 chimeras, stroma and PrP-deficient
spleen cells contained similar amounts of scrapie prions, as
assessed by bioassay with indicator animals (Fig. 4C): infec-
tivity ranged from 4.8 to 5.8 log LD50 in both fractions. To
exclude contamination of spleen cells with components of the
stroma which might nonspecifically pollute fractions with pri-
ons, we performed PCR analyses of these subsets and trans-
mitted purified B, T, and non-B/T cells to tga20 mice. Whereas
B and T cells contained 3.3 and 2.4 log LD50 34 days after i.p.
inoculation, very low amounts of infectivity could be recovered
in the non-B/T cells, as well as in B- and T-cell fractions at later
time points (Fig. 4C). PCR analysis of these infectious spleen
cells, B cells, T cells, and non-B/T cells confirmed the Prnpo/o
genotype of these fractions (Fig. 4F). Prions could not be
detected in WBCs of any of the reconstituted mice or in WBCs
of control mice (Fig. 4B to E).
Prion replication requires PrPc, and mice deficient in PrPc
are unable to accumulate prion infectivity in the spleen and
brain (10, 43). However, scrapie developed in three of four
tga20 indicator animals challenged with a whole spleen homog-
enate derived from a Prnpo/o mouse that had been reconsti-
tuted with Prnpo/o FLCs 34 days after inoculation (Table 1). No
infectivity was detected at later time points in any of the mice
belonging to the same experimental group. This is in agree-
ment with earlier findings (43) and is most probably explained
by the occasional persistence of traces of residual inoculum.
Detection of anti-PrP antibodies in sera of inoculated mice.
We searched for anti-PrP antibodies in mice devoid of PrPc
200 days after inoculation to investigate whether the clearance
of the infectious agent might be due to a specific immune re-
sponse to the RML inoculum. The sera of seven PrP-deficient
mice reconstituted with Prnpo/o FLCs were assayed. Only one
chimera had a titer higher than two times above the back-
ground titer. Two additional mice had a titer close to twice the
background titer. The remaining four animals did not display
detectable anti-PrP antibody titers (data not shown).
DISCUSSION
The nature of cells replicating prions in the periphery, and
the precise role of Prnp expression in these cells, is still unclear.
A likely candidate for a lymphoreticular prion replication site
is the FDC (9, 22, 36), but experimental evidence has so far not
been conclusive. FDCs are sessile cells located in germinal
centers of lymphoid organs which act as antigen traps and
support affinity maturation of B lymphocytes. Although their
origin remains controversial, there is general agreement that
they are not significantly replaced by transfer of FLCs into
adult mice (19, 49) but, due to the expression of fibroblast
antigens (7), may originate from the fibroblastic reticulum. It
has not been possible to recover prions from FDC-deficient
FIG. 4. Distribution of prions in spleens of scrapie-infected mice. (A) FACS analysis of MACS-purified spleen cell fractions originating from
scrapie-infected mice. MACS sorting resulted in .97% of the sorted cell type; therefore cross-contamination could be excluded to a large extent.
Anti-CD45R (B220) antibodies were used to label B cells, and anti-CD90.2 (Thy 1.2) was used for T cells. Gating for lymphocytes by forward and
side scattering did not interfere with the readout. (B to E) Infectivity levels in splenic fractions and WBCs of FLC-reconstituted and control mice.
Fractions were transmitted i.c. in groups of three to four tga20 indicator mice. Symbols: blue circles, spleen cells; blue triangles, B cells; blue
inverted triangles, T cells; blue crosses, non-B/T cells; red crosses, stromal fraction; black rhombi, WBCs. Within-group standard deviations are
indicated only if they exceed 60.15 log LD50. Infectivity contents relate to each cellular fraction of individual spleens. (Footnotes) a, similar groups
of cell subsets were transmitted after primary inoculation with 3 log LD50; all these fractions were devoid of prions. b, in each of the two separate
transmissions of the stromal fraction of this group, all four indicator animals died of intercurrent death within 72 h after i.c. administration, most
likely due to brain emboli or toxic contaminations of this homogenate. If one or more animals survived .180 days, the titer was assumed to be
close to the detection threshold of the bioassay. For these samples (labeled with small italic letters), the number of animals succumbing to scrapie
out of the number of indicator animals inoculated and, in parentheses, incubation time (days) to terminal scrapie in individual mice were as follows:
c, one of three (157); d, two of four (110, 116); e, one of four (128); f one of four (115); g, two of four (90, 145); h, two of four (87, 90); i, two of
three (90, 93). (F) PCR of spleen cells and splenic B, T, and non-B/T cells. Infectious splenic lymphocytes, derived 34 days after primary inoculation
from Prnp1/1 mice reconstituted with Prnp null FLCs, were tested for the presence of the Prnp gene by PCR. Only the Prnpo/o genotype of
reconstituting cells was identified in these infectious splenic cell fractions. Prion contents are indicated in log LD50 per fraction of each spleen.
k,
sample derived from spleen cells known to contain Prnp1/1 and Prnpo/o DNA.
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spleens derived, e.g., from mice deficient in tumor necrosis
factor alpha (TNF-a2/2 mice) (33), nor could PrPSc be visu-
alized in spleens of lymphotoxin b-deficient (LTb2/2) mice
(35). Notwithstanding the strong experimental evidence that
FDCs are involved in prion pathogenesis, there are several
findings that point to an additional role of lymphocytes in prion
neuroinvasion after peripheral infection. While the presence of
B cells is crucial for neuroinvasion after peripheral chal-
lenge (24), the main role of B cells in pathogenesis may
consist of supporting FDCs by providing lymphotoxin signal-
ing. In tumor necrosis factor receptor 1-deficient (TNFR12/2)
mice, which lack mature FDCs in their spleens (31), develop-
ment of cerebral disease after peripheral challenge with RML
scrapie is unaffected (24), and spleens of TNFR12/2 mice con-
tain only traces of infectivity (M. A. Klein, F. Montrasio, M.
Prinz, and A. Aguzzi, unpublished results). In addition, it was
reported that LTb2/2 mice, which suffer from a similar defect
in FDC maturation (26), may be as susceptible to infection
with CJD prions as wild-type mice, although pathologic PrP
could not be visualized in spleens and lymph nodes (35). How-
ever, the latter study may not be fully representative, since no
transmission studies of spleens or lymph nodes were reported.
Further, in vivo ablation of FDCs by administration of a sol-
uble lymphotoxin b receptor, while efficiently preventing the
buildup of a splenic prion burden (36), does not fully shelter
the brain from neuroinvasion (32, 36).
In view of the uncertainties delineated above, we first as-
sessed whether prions actively replicate, or just accumulate, at
peripheral sites after i.p. infection. Regardless of the dose of
the primary inoculum administered (6 or 3 log LD50 i.p.),
wild-type spleens contained 5 to 7 log LD50 of scrapie infec-
tivity at early time points after peripheral challenge (Table 1),
yielding strong evidence for peripheral prion replication. This
is in line with the data recorded in transgenic mouse lines
showing peripheral replication of a scrapie agent in mice (41).
To investigate the significance of the PrP status of immune
cells during peripheral pathogenesis of scrapie disease, we
constructed reciprocal fetal liver chimeras with wild-type
(Prnp1/1) mice and with a genetically altered mouse line of the
Prnpo/o genotype. A limiting dose of prions (3 log LD50) never
produced detectable levels of prion infectivity in spleens of
animals with compartment-restricted Prnp expression, indicat-
ing that these chimeras were not able to effectively replicate or
store the infectious agent. We therefore conclude that expres-
sion of PrPc both in LSCs and in a sessile, radioresistant cel-
lular compartment (most likely consisting of FDCs) is needed
for efficient splenic capture and replication of prion infectivity.
Spleens with PrPc expression confined to LSCs are able to
chronically accumulate prions over a time course of at least 200
days after i.p. inoculation with a saturating dose of prions (6
log LD50). These findings confirm and extend our previously
published experiments in which long-term prion persistence
was detected in Prnpo/o mice bearing a Prnp1/1 brain graft and
Prnp1/1 hematopoietic cells (5). Therefore, PrPc expression by
the host is not absolutely required for splenic prion accumu-
lation. This result is in contrast with the findings reported by
Brown et al. (9), who performed similar experiments with ME7
prions, and may point to differences in the cellular tropism of
different prion strains.
Astonishingly, the bulk of prion infectivity in Prnp1/13
Prnpo/o chimeras was located within the stromal compartment,
even if the Prnp1/1 genotype was confined to hematopoietic
cells. At least two hypotheses could explain this finding: (i)
Prnp-deficient FDCs could acquire PrPc or prions from LSCs,
or (ii) the Prnp1/13Prnpo/o FLC reconstitution could have
induced development of Prnp1 FDCs from hypothetical pre-
cursors within FLCs (19, 49), which may acquire and replicate
prion infectivity. We consider the second hypothesis to be
improbable since previous analyses do not indicate that FDCs
can be efficiently reconstituted by FLCs (19, 49). Conversely,
after i.p. challenge with a saturating dose of prions (6 log
LD50), spleens of wild-type mice grafted with Prnp
o/o FLCs
contained 6.1 to 7.2 log LD50 of infectivity. The prion loads of
spleen cells and stromal fractions were similar, i.e., 5.0 to 6.0
log LD50. Therefore, Prnp-deficient spleen cells (whose pure
Prnpo/o genotype was confirmed by PCR analysis) were able to
transmit relatively high infectivity titers to indicator animals.
When separated B, T, and non-B/T cells of the same chimeras
were transmitted, the resulting findings were consistent with
this PrP-independent association of infectivity in spleen cells:
highly purified B and T lymphocytes of Prnpo/o origin were able
to infect indicator animals. Consequently, splenic lymphocytes
of mice infected i.p. with large amounts of prions do not
require a Prnp1 allele in order to transmit prions to indicator
animals.
The mechanism of chronic spleen infection in mice with
compartment-restricted expression of Prnp after challenging
with a saturating dose of prions remains unclear. It is possible
that under these circumstances prions undergo very slow
splenic replication and reach an equilibrium with elimination
of infectivity. PrPc is a glycophosphatidylinositol-anchored pro-
tein (46), and since these proteins can easily transfer from one
cell to another (3, 27), it is conceivable that “painting” of the
Prnpo/o compartment by PrPc-positive cells results in acquisi-
tion of a PrPc-positive phenotype and, possibly, in restored
support of low-level prion replication.
Alternatively, the original inoculum may be chronically
stored: other antigens, such as human immunodeficiency virus
type 1 virions (44, 45) and human serum albumin (47), are
known to be retained on the plasma membrane of FDCs for
months or even years (23, 34, 48). The immunological or cel-
lular mechanism of such retention may be independent of
PrPc: molecules acting as partners of antigen presentation like
complement factors (25) or Fcg receptors (11) are likely to be
involved. In fact, it has been recently reported that disease-
specific PrPSc is detectable ultrastructurally on the surface of
FDCs, where it colocalizes with complement and Fcg receptors
(18).
The mismatch between the level of infectivity in spleen cells
and the sum of the corresponding subpopulations in all exper-
imental groups is most probably due to the extensive washing
procedure associated with MACS and could represent a con-
sequence of the interaction between lymphocytes and prions.
Therefore, the association of prions with lymphocytes may be
rather loose.
After inoculation with 4.5 log LD50 of prions (30 times less
than in the present report), infectivity was associated with
spleen cells expressing PrPc but not with Prnpo/o spleen cells
(40). The present results indicate that upon a primary i.p.
inoculation with 6 log LD50, prions were associated with spleen
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cells and with highly purified lymphocyte fractions regardless
of PrPc expression. This discrepancy points to a possible dose
dependence of the Prnp-independent capture of prions by lym-
phocytes.
Furthermore, the present study shows that inoculation with
3 log LD50 of scrapie prions, which corresponds to a 30-fold
dilution of the dose used by Raeber and colleagues (40), results
in a loss of splenic infectivity both in fetal liver chimeras, with
ablation of Prnp in the donor, and in reciprocal chimeras with
a Prnpo/o recipient. To investigate whether the loss of prions
in mice devoid of the Prnp gene might be due to a humoral
immune response (2) to the prion protein, we screened sera for
anti-PrP antibodies. In only one of seven animals, we found a
titer that was more than twice the background titer. We con-
clude that the infectivity clearance in these animals is unlikely
to be due to a persisting humoral immune response to PrP.
While the precise mechanism of clearance remains unclear,
removal of Prnp in either compartment appears to decrease
the overall efficiency of the lymphoreticular phase of prion
replication.
After replicating in the germinal center, prions find access to
the central nervous system. As indicated in previous studies
(39), peripheral nerves are likely to be the final common path-
way for neuroinvasion. How interactions between the periph-
eral nervous system and FDCs occur (14) and whether lym-
phocytes may contribute to the transport of scrapie prions
within the spleen remain to be elucidated.
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